Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2003 Jun 1;372(Pt 2):643–649. doi: 10.1042/BJ20021670

Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor.

Sara Deakin 1, Ilia Leviev 1, Marie-Claude Brulhart-Meynet 1, Richard W James 1
PMCID: PMC1223427  PMID: 12639220

Abstract

Accumulating data suggest that paraoxonase-1 (PON1) is a primary determinant of the antioxidant and anti-inflammatory capacities of high-density lipoproteins (HDLs). Variations in HDLs and PON1 have been shown to influence the functions of both. There is a wide spectrum of serum PON1 mass in humans, to which promoter polymorphisms make an important contribution. The present studies attempted to define: (i) the relevance in vivo of promoter polymorphisms by analysing haplotype structure; and (ii) molecular mechanisms implicated in promoter activity. Highly significant differences (P <0.0001) in serum mass and activity were observed as a function of haplotype sequence. Of three promoter polymorphisms (-107, -824 and -907), the -107 site was shown to be of predominant importance to serum PON1. Significant increases in serum PON1 mass and activities between haplotype subgroups could be explained by unit increases in the number of high-expresser variants of the -107 site (-107C) alone. No significant contribution was observed for the -824 and -907 sites. The coding-region Leu(55)-->Met (L55M) polymorphism made an independent contribution to serum PON1 mass, which may account for variations in serum PON1 mass and activity within haplotype subgroups defined by the -107 site. A molecular basis for the effect of the -107 polymorphism on serum PON1 was indicated by the greater affinity of the high-expresser variant (-107C) for hepatocyte nuclear extracts, indicating higher affinity for transcription factors. Competition studies with oligonucleotides representing the consensus (and mutated) sequence for Sp1, and the use of Sp1 antibodies, confirmed formation of complexes between the transcription factor and the PON1 promoter during incubation with nuclear extracts. The data underline the importance of the region containing the C(-107)T polymorphism for gene expression in vivo. Differences in the affinity of the -107C and -107T polymorphic fragments for nuclear extracts have been demonstrated, and coincide with their impact on gene expression. A potential role for the transcription factor Sp1 has been demonstrated, which is consistent with the disruption of an Sp1 recognition sequence by the -107 polymorphism.

Full Text

The Full Text of this article is available as a PDF (160.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adkins S., Gan K. N., Mody M., La Du B. N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993 Mar;52(3):598–608. [PMC free article] [PubMed] [Google Scholar]
  2. Antikainen M., Murtomäki S., Syvänne M., Pahlman R., Tahvanainen E., Jauhiainen M., Frick M. H., Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 1996 Aug 15;98(4):883–885. doi: 10.1172/JCI118869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000 May 30;101(21):2510–2517. doi: 10.1161/01.cir.101.21.2510. [DOI] [PubMed] [Google Scholar]
  4. Blatter Garin M. C., Abbott C., Messmer S., Mackness M., Durrington P., Pometta D., James R. W. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994 Dec 1;304(Pt 2):549–554. doi: 10.1042/bj3040549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brophy V. H., Hastings M. D., Clendenning J. B., Richter R. J., Jarvik G. P., Furlong C. E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 2001 Feb;11(1):77–84. doi: 10.1097/00008571-200102000-00009. [DOI] [PubMed] [Google Scholar]
  6. Brophy V. H., Jampsa R. L., Clendenning J. B., McKinstry L. A., Jarvik G. P., Furlong C. E. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001 May 2;68(6):1428–1436. doi: 10.1086/320600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Castellani L. W., Navab M., Van Lenten B. J., Hedrick C. C., Hama S. Y., Goto A. M., Fogelman A. M., Lusis A. J. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest. 1997 Jul 15;100(2):464–474. doi: 10.1172/JCI119554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edwards P. A., Tabor D., Kast H. R., Venkateswaran A. Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta. 2000 Dec 15;1529(1-3):103–113. doi: 10.1016/s1388-1981(00)00140-2. [DOI] [PubMed] [Google Scholar]
  9. Garin M. C., James R. W., Dussoix P., Blanché H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997 Jan 1;99(1):62–66. doi: 10.1172/JCI119134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Herrmann S. M., Blanc H., Poirier O., Arveiler D., Luc G., Evans A., Marques-Vidal P., Bard J. M., Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 1996 Oct 25;126(2):299–303. doi: 10.1016/0021-9150(96)05917-5. [DOI] [PubMed] [Google Scholar]
  11. Humbert R., Adler D. A., Disteche C. M., Hassett C., Omiecinski C. J., Furlong C. E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993 Jan;3(1):73–76. doi: 10.1038/ng0193-73. [DOI] [PubMed] [Google Scholar]
  12. Jakubowski H., Ambrosius W. T., Pratt J. H. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001 Feb 23;491(1-2):35–39. doi: 10.1016/s0014-5793(01)02143-3. [DOI] [PubMed] [Google Scholar]
  13. James R. W., Leviev I., Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 2000 May 16;101(19):2252–2257. doi: 10.1161/01.cir.101.19.2252. [DOI] [PubMed] [Google Scholar]
  14. James R. W., Leviev I., Ruiz J., Passa P., Froguel P., Garin M. C. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes. 2000 Aug;49(8):1390–1393. doi: 10.2337/diabetes.49.8.1390. [DOI] [PubMed] [Google Scholar]
  15. Jarvik G. P., Rozek L. S., Brophy V. H., Hatsukami T. S., Richter R. J., Schellenberg G. D., Furlong C. E. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2441–2447. doi: 10.1161/01.atv.20.11.2441. [DOI] [PubMed] [Google Scholar]
  16. Ko Y. L., Ko Y. S., Wang S. M., Hsu L. A., Chang C. J., Chu P. H., Cheng N. J., Chen W. J., Chiang C. W., Lee Y. S. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis. 1998 Dec;141(2):259–264. doi: 10.1016/s0021-9150(98)00179-8. [DOI] [PubMed] [Google Scholar]
  17. Leviev I., Deakin S., James R. W. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res. 2001 Apr;42(4):528–535. [PubMed] [Google Scholar]
  18. Leviev I., James R. W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):516–521. doi: 10.1161/01.atv.20.2.516. [DOI] [PubMed] [Google Scholar]
  19. Mackness B., Davies G. K., Turkie W., Lee E., Roberts D. H., Hill E., Roberts C., Durrington P. N., Mackness M. I. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1451–1457. doi: 10.1161/hq0901.094247. [DOI] [PubMed] [Google Scholar]
  20. Mackness M. I., Durrington P. N., Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol. 2000 Aug;11(4):383–388. doi: 10.1097/00041433-200008000-00007. [DOI] [PubMed] [Google Scholar]
  21. Navab M., Hama S. Y., Hough G. P., Hedrick C. C., Sorenson R., La Du B. N., Kobashigawa J. A., Fonarow G. C., Berliner J. A., Laks H. High density associated enzymes: their role in vascular biology. Curr Opin Lipidol. 1998 Oct;9(5):449–456. doi: 10.1097/00041433-199810000-00009. [DOI] [PubMed] [Google Scholar]
  22. Palmer G., Manen D., Bonjour J. P., Caverzasio J. Species-specific mechanisms control the activity of the Pit1/PIT1 phosphate transporter gene promoter in mouse and human. Gene. 2001 Nov 14;279(1):49–62. doi: 10.1016/s0378-1119(01)00747-8. [DOI] [PubMed] [Google Scholar]
  23. Pfohl M., Koch M., Enderle M. D., Kühn R., Füllhase J., Karsch K. R., Häring H. U. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 1999 Mar;48(3):623–627. doi: 10.2337/diabetes.48.3.623. [DOI] [PubMed] [Google Scholar]
  24. Ruiz J., Blanché H., James R. W., Garin M. C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995 Sep 30;346(8979):869–872. doi: 10.1016/s0140-6736(95)92709-3. [DOI] [PubMed] [Google Scholar]
  25. Salonen J. T., Malin R., Tuomainen T. P., Nyyssönen K., Lakka T. A., Lehtimäki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. BMJ. 1999 Aug 21;319(7208):487–490. doi: 10.1136/bmj.319.7208.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schreiber E., Matthias P., Müller M. M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 1989 Aug 11;17(15):6419–6419. doi: 10.1093/nar/17.15.6419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Serrato M., Marian A. J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995 Dec;96(6):3005–3008. doi: 10.1172/JCI118373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Shih D. M., Gu L., Xia Y. R., Navab M., Li W. F., Hama S., Castellani L. W., Furlong C. E., Costa L. G., Fogelman A. M. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998 Jul 16;394(6690):284–287. doi: 10.1038/28406. [DOI] [PubMed] [Google Scholar]
  29. Shih D. M., Xia Y. R., Wang X. P., Miller E., Castellani L. W., Subbanagounder G., Cheroutre H., Faull K. F., Berliner J. A., Witztum J. L. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000 Jun 9;275(23):17527–17535. doi: 10.1074/jbc.M910376199. [DOI] [PubMed] [Google Scholar]
  30. Suehiro T., Nakamura T., Inoue M., Shiinoki T., Ikeda Y., Kumon Y., Shindo M., Tanaka H., Hashimoto K. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis. 2000 Jun;150(2):295–298. doi: 10.1016/s0021-9150(99)00379-2. [DOI] [PubMed] [Google Scholar]
  31. Tward Aaron, Xia Yu-Rong, Wang Xu-Ping, Shi Yi-Shou, Park Christina, Castellani Lawrence W., Lusis Aldons J., Shih Diana M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002 Jul 23;106(4):484–490. doi: 10.1161/01.cir.0000023623.87083.4f. [DOI] [PubMed] [Google Scholar]
  32. Van Lenten B. J., Wagner A. C., Nayak D. P., Hama S., Navab M., Fogelman A. M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001 May 8;103(18):2283–2288. doi: 10.1161/01.cir.103.18.2283. [DOI] [PubMed] [Google Scholar]
  33. Zama T., Murata M., Matsubara Y., Kawano K., Aoki N., Yoshino H., Watanabe G., Ishikawa K., Ikeda Y. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3565–3569. doi: 10.1161/01.atv.17.12.3565. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES